In a double blind randomized study, the bisphosphonate drug Pamidronate (Aredia) significantly protected Durie-Salmon stage III multiple myeloma patients from osteolytic bone disease. In the patient sub-group on salvage chemotherapy. Pamidronate treatment was also significantly associated with prolonged survival. To test if this drug could induce direct antitumor effects, we exposed myeloma cells to increasing concentrations of Pamidronate or a more potent bisphosphonate, Zoledronate. A concentration-and time-dependent cytotoxic effect was detected on four of five myeloma cell lines as well as three specimens obtained directly from myeloma patients. Zoledronate-induced cytotoxicity was significantly greater than that of Pamidronate. Cytotoxicity could not be explained by bisphosphonate-induced chelation of extracellular calcium or secondary decrease in production of the myeloma growth factor interleukin-6. Morphological examination, DNA electrophoresis and cell cycle analysis indicated that the bisphosphonate-induced cytotoxic effect consisted of a combination of cytostasis and apoptotic myeloma cell death. Enforced expression of BCL-2 protected against the apoptotic death but not against cytostasis. Most cytotoxic effects were seen between 10 and 100 M of drug. The results suggest a possible direct anti-tumor effect in myeloma patients treated with bisphosphonates which may participate in their significantly increased survival. This hypothesis should now be further tested in clinical trials.
Introduction
Bisphosphonates are a new class of drugs that inhibit osteoclast activation (reviewed in Ref. 1) . As such, they have been shown to be efficacious in preventing osteoclast-mediated osteolytic bone disease in several different malignancies. [2] [3] [4] In a randomized, double blind, phase III study, 3 the second generation bisphosphonate Aredia (Pamidronate) prevented bony complications in patients with active Durie-Salmon stage III multiple myeloma (MM). The incidence of pathologic fracture, the use of radiotherapy to skeletal sites of disease, bone pain, and the need for narcotic analgesia were all significantly reduced in Aredia-treated patients. There was also a significant prolongation of survival in the Aredia arm of the trial in patients who were on salvage chemotherapy. 5 This survival advantage might simply reflect an improved quality of life with its attendant increased mobility and decreased rate of medical complications such as infection. However, it is also possible that Aredia induced an anti-tumor effect resulting in longer survival. In this regard, bisphosphonates not only inhibit osteoclast bone resorption but are actually cytotoxic to osteoclasts, 6 inducing an apoptotic death. These drugs can also induce apoptosis of monocytes. 7 To further investigate their potential as anti-myeloma agents, we initiated the current study, exposing multiple myeloma cell lines as well as primary MM plasma cell specimens obtained from patients to increasing concentrations of Aredia as well as the third generCorrespondence: A Aparicio; Fax: 310 268 4908 Received 5 June 1997; accepted 1 October 1997 ation, more potent bisphosphonate Zoledronate. The results indicate the ability of these drugs to inhibit growth of myeloma cells. The induction of apoptotic death of plasma cells was also detected. The data suggest the possibility that these drugs may have a myeloma-cytoreductive effect in treated patients and indicate that an appropriate phase II clinical trial of these drugs is warranted in this disease.
Materials and methods

Cell lines
The U266, IM-9 and ARH-77 cell lines were obtained from ATCC. The 8226 line was a kind gift of J Epstein (University of Arkansas, Little Rock, AR, USA). The OCI-My 1 cell line was a kind gift of Dr HA Messner (University of Toronto, Toronto, Canada). All cell lines except OCI-My 1 were maintained in RPMI media, supplemented with 10% fetal bovine serum, L-glutamine, non-essential amino acids, sodium pyruvate and antibiotics. The OCI-My 1 line was maintained in Iscove's medium, supplemented with 20% human serum and 50 mol/l 2-mercaptoethanol.
Reagents
Aredia and Zoledronate were kind gifts from Dr Jonathan Green (Novartis, Basel, Switzerland). Recombinant interleukin-6 (IL-6) was purchased from Genzyme (Cambridge, MA, USA). Anti-fas antibody was purchased from Kamiya (Thousand Oaks, CA, USA). All other reagents were purchased from Sigma (St Louis, MO, USA).
Dye exclusion assay
Exponentially growing cells were seeded at an initial concentration of 2-4 × 10 5 /ml in six-well tissue culture plates. Drugs were added at specified concentrations. At varied time points, viability was determined by trypan blue staining (determined in at least 300 cells/group). Triplicate wells were run for each group and the standard deviation (s.d.) of the groups was always Ͻ5% of the mean viability. The total number of viable cells was also calculated and percent viable cell recovery in the bisphosphonate-treated groups was determined by comparison to control cultures that were not exposed to any drugs. Thus, enumeration of total number of viable cells will be an assessment of the combined effects of cytostasis (inhibition of proliferation relative to control, untreated cultures) and cytolysis (induction of target cell death).
Determination of percent apoptosis in stained slides
Cells from the above-described dye exclusion assays were used to generate cytopreparations on slides which were subsequently stained with Wright-Giemsa. The percent of stained cells that demonstrated apoptotic morphology was determined by counting 400 total cells per experimental group. Apoptotic cells were easily identified (see Figure 5 ) as being considerably smaller, with cytoplasmic blebbing and/or nuclear fragmentation.
MTT assay
The MTT assay was performed as previously described 8 by seeding 1-2 × 10 4 target cells in 0.1 ml of complete media into wells of a 96-well microtiter plate. At varying incubation times, the reduction of MTT to formazan by live cells was determined with a microplate ELISA reader equipped with a 570 nm filter. Quadruplicate wells were run for each group and the s.d. of each group was always Ͻ5% of the mean. Results are presented as percent cytotoxicity determined as (1-ODexp group/ODcontrol group) × 100. As formazan staining is directly related to the number of viable cells, the MTT cytotoxicity assay is similar to the enumeration of total viable cells in that it also measures the combined effects of cytostasis and cytolysis.
DNA electrophoresis
As previously described, 9 cells were exposed to lysis buffer for 18 h at 37°C. DNA was then extracted with phenol, chloroform and isoamyl alcohol. Electrophoresis of 10-30 g aliquots of total cellular DNA was performed in 1% agarose gels with HindIII digests of lambda DNA and MspI digests of pBR322 DNA as standards. Gels were visualized with ethidium bromide staining.
BCL-2 transfection
As previously described, 10 IM-9 cells were transfected with the pCI expression vector containing the BCL-2 cDNA subcloned at EcoRI sites. IM-9 control cells were also transfected with the empty vector. Transfection was performed by lipofection as previously described. 10 After selection in 800 g/ml of G418, polyclonal populations of transfected cells were studied by Western analysis for BCL-2 expression. As previously demonstrated, 10 BCL-2-transfected cells overexpress BCL-2 protein (approximately 5-fold over neo-control cells), and are resistant to doxorubicin and etoposide.
Cell cycle analysis
Cells were stained with hypotonic propidium iodide (PI) (50 g/ml in 0.1% sodium citrate and 0.1% Triton X-100) for 1 h at 4°C. They were kept in the dark at 4°C before analysis. Cell cycle distribution was then determined by analyzing 10 000 events on a FACScan flow cytometer (Becton Dickinson). The DNA data was fitted to a cell cycle distribution analysis by use of the MODFIT program for MAC V2.0.
Statistics
The t-test was used to determine statistical significance of detected differences.
Results
Aredia and Zoledronate induce cytotoxicity to myeloma cell lines
Initial experiments monitored possible cytotoxic effects induced by Pamidronate (Aredia) by use of an MTT assay and by counting viable cell recovery in dye exclusion assays. Although we have defined the results of the MTT assay as 'percent cytotoxicity', it is a measure of the combined effects of cytostasis (inhibition of proliferation) and cytolysis (induction of target cell death). Similarly, the results of viable cell recovery are measures of the combined effects of cytostasis and cytolysis. As shown in Figure 1 , a significant adverse effect of Aredia was demonstrated by both assays on 8226 and IM-9 MM cell lines after 48 h of exposure. In contrast, ARH-77 MM cells were resistant. Of these cell lines, 8226 cells were the most sensitive, showing a slow increase in cytotoxicity until approximately 10 M, after which the cytotoxicity curve demonstrated a steep concentration-dependence between 10 and 100 M. IM-9 target cells showed only modest sensitivity with significant cytotoxicity only demonstrated at 100 M of drug. The dye exclusion assays demonstrated that, not only was there a decreased recovery of Arediatreated 8226 cells, but also obvious cytolysis (target cell death). The percent viability at 48 h in 8226 targets treated in media (control), 10, 50 and 100 M of Aredia were 92 ± 2,
Figure 1
Cytoreductive effects of Pamidronate against MM cell lines. 8226 (᭡), IM-9 (b) or ARH-77 () cells cultured with increasing concentrations of Pamidronate (Aredia) for 48 h, after which cells were assayed by trypan blue exclusion to determine % recovery (relative to non-treated control cells) or by MTT assay to determine % cytotoxicity. Data is mean ± s.d. of five separate experiments. Significant cytotoxicity and decreased recovery was seen in 8226 cells cultured with 10, 50, and 100 M Aredia and in IM-9 cells cultured with 100 M (P Ͻ 0.05).
79 ± 3, 51 ± 4 and 12 ± 3%, respectively. Thus, the in vitro cytoreductive effect of Aredia cannot be completely explained by cytostasis as cell death is also induced.
When the more potent bisphosphonate Zoledronate was used, the resulting cytotoxicity in the same MM cell lines was significantly increased (Figure 2 ). Although ARH-77 cells were still resistant, there was an increase in cytotoxicity to 8226 targets (compared to Aredia) as well as IM-9 cells. In MTT assays, the LD50 for 8226 decreased from 60 M (when treated with Aredia) to 9 M (due to Zoledronate) and, in dye exclusion assays, from 40 M to 6.5 M. Zoledronate-treated IM-9 cells demonstrate an LD50 of 55 M in MTT assays and 20 M in dye exclusion assays. The relative differences in sensitivity to cytotoxicity between these cell lines was specific for bisphosphonates. For example, although 8226 cells were consistently more sensitive to bisphosphonates than IM-9 cells, they were comparable in their sensitivity to doxorubicin (IC 50 for 8226 = 0.2 M; IM-9 = 0.17 M after 24 h by dye exclusion assay) and etoposide (IC 50 = 0.3 M for both cell lines). Additional experiments (not shown) demonstrated that ARH-77 cells' sensitivity to anti-fas-induced apoptosis is at least comparable to the sensitivity of the 8226 cell line. This is consistent with a prior report. 11 Thus, this target's resistance to bisphosphonates is not explained by a non-specific generalized resistance to all apoptotic injury.
Not shown in Figures 1 and 2 are results of experiments with U266 and OCI-My 1 MM cell lines. Aredia and Zoledronate also had modest concentration-and time-dependent cytoreductive effects in these cells. After 48 h of exposure, Zoledronate (100 M) induced a decreased recovery of live U266 cells to 60% of control (there was no significant effect after only 24 h in culture). Likewise, after 72 h of culture, 12 that collects high CD38-expressing cells when used with a biotinylated murine anti-CD38 antibody. All three fresh MM cell suspensions consisted of Ͼ94% plasma cells as detected in Giemsa-stained cytopreparations. As shown in Table 1 , both Aredia and Zoledronate induced significant dose-dependent cytoreductive effects on these fresh MM samples. However, the effect on tumor target No. 2 required Ͼ72 h of exposure to be detected.
Bisphosphonate-induced cytotoxicity is not due to calcium chelation or inhibition of IL-6-induced MM cell growth or survival
Bisphosphonates are known to chelate calcium 13 and it was, thus, possible that the observed MM cell cytotoxicity was indirectly due to removal of calcium from the culture media.
To test this, we compared the effects of bisphosphonates on sensitive MM cells to the effects of the calcium chelator EGTA in MTT assays. As shown in Figure 3 , EGTA (E) at 100 M had no effect on the sensitive myeloma cells IM-9 (a), or 8226 (b) while 50 or 25 M of Zoledronate (Z), as demonstrated above, was significantly cytotoxic. Thus, the cells were resistant to the calcium-chelation effects of a two-to four-fold greater concentration of EGTA. Furthermore, addition of EGTA to either 50 M or 25 M of Zoledronate resulted in a significant decrease in cytotoxicity (Figure 3 ) rather than an enhanced cytotoxic effect which one would expect if the bisphosphonates were working via chelation of calcium. These data indicate the cytotoxic effects of bisphosphonates are not an artifact due to calcium chelation and, furthermore, suggest that a decrease in extracellular concentration can actually protect MM targets from these drugs.
We have also detected a significant inhibition of IL-6 production from MM stromal cell monolayers incubated with bisphosphonates.
14 Although the cell lines sensitive to the cytotoxic effects of bisphosphonates shown in Figures 1 and  2 are not known to produce any detectable IL-6 (Ref. 15 and our own unpublished data), to undoubtedly rule out the possibility that bisphosphonate-induced cytotoxicity is secondary to a decrease in autocrine IL-6 production, the targets were exposed to Aredia or Zoledronate in the presence of IL-6 (1000 U/ml). As shown in Figure 4 , this very high concentration of IL-6 had no effect on cytotoxicity to 8226 or IM-9 cells detected in MTT or dye exclusion assays, while showing a positive survival effect in 8226 cells challenged with antifas antibody. These protective effects of IL-6 against fasinduced death are consistent with previous work. 16 Thus, bisphosphonate-induced death of 8226 or IM-9 cells is not due to effects on IL-6 secretion. The U266 cell line, however, does display autocrine IL-6 growth stimulation. 17 Thus, in additional experiments, we tested the effects of exogenous IL-6 on the cytotoxicity of bisphosphonates to the U266 cell line. Zoledronate (100 M) decreased U266 recovery to 63% of control after 48 h of exposure (mean of three experiments) and the addition of IL-6 (1000 U/ml) to the culture had no effect on this cytotoxicity (60% of control). These data rule out the possibility that the cytoreductive effects of bisphosphonates on these MM cell lines is due to an inhibition of MM cell IL-6 production.
Bisphosphonate-induced MM cell death is due to apoptosis
Since bisphosphonates can induce apoptosis in other cell types, 6, 7 we examined MM cells for programmed cell death. Apoptosis was studied in a multiparameter fashion by morphologic examination, DNA electrophoresis and flow cytometry. Morphologic examination of treated MM cells demonstrated alterations consistent with apoptosis ( Figure 5 ). As shown, apoptotic cells became smaller and exhibited fragmented nuclei and cytoplasmic blebbing. This was evident in cell lines as well as freshly obtained MM cells from patients (Figure 5d-f) . DNA electrophoresis confirmed the ability of these drugs to induce apoptotic fragmentation ( Figure 6 ). In addition, the DNA fragmentary changes in cell lines correlated well with the sensitivity in cytotoxicity assays: 8226 cells demonstrated ladder-like fragmentation when exposed to Aredia or Zoledronate ( Figure 6, lanes 7, 15 and 16 ), IM-9 cells only demonstrated fragmentation when exposed to Zoledronate (lanes 4 and 10) and ARH-77 cells retained high molecular weight intact DNA (lanes 18 and 19) . Flow cytometric analysis also revealed a significant induction of apoptosis along with an increase in the distribution of cells in S phase. As shown in Figure 7 , apoptotic cells were detected as a significant sub-G1 shoulder on cell cycle analysis (arrows, b, c, e and f). The increase in S phase distribution was impressive and was associated with a marked reciprocal decrease in cells in G2-M.
The percent of cells in S phase (hatched lines) increased in
Figure 4
8226 or IM-9 cells cultured with Aredia or Zoledronate (100 M) ± IL-6 1000 U/ml for 48 h and % recovery of both targets and % cytotoxicity of only 8226 targets was assayed. The MTT assay for IM-9 cells treated with bisphosphonates ± IL-6 was not performed in this experiment and no bars are shown. Anti-fas treatment was at 1 g/ml for 24 h ± 1000 U/ml of IL-6. Anti-fas-induced effects are compared to control cultures exposed to a control antibody of identical isotype. Data are mean ± s.d. of quadruplicate samples. The only significant difference in cytotoxicity or recovery induced by IL-6 was in 8226 cells treated with anti-fas (P Ͻ 0.05). The experiment was repeated with identical results. (Figure 7 ) while the percent in G2-M decreased from 10.3% to 7% and 0.01%, respectively. Furthermore, in these same experiments, concentrations of Aredia or Zoledronate that had no effect on viable cell recovery or MTT cytotoxicity (1-10 M) did not significantly alter cell cycle distribution (data not shown).
Bisphosphonate-induced myeloma cell death is prevented by ectopic BCL-2 expression
To test whether BCL-2 can protect plasma cells from bisphosphonate-induced apoptosis, IM-9 cells were transfected with an expression vector containing the full length BCL-2 cDNA or a neo-control empty vector. After selection in G418, transfected cells demonstrated heightened BCL-2 expression, which was five-fold greater than parent or neo-control transfected cells. 10 These cell populations were then tested for sensitivity to Zoledronate by assessing viability in trypan blue exclusion assays and degree of apoptosis in examination of Giemsa-stained cytopreps. The viability and percent of cells with apoptotic morphology in cultures of parental cells was almost identical to the neo-control culture and Figure 8 only compares the neo-control cells to the BCL-2-transfected cells. As shown, neo-control cells demonstrated a concentrationand time-dependent loss of viability and a corresponding increase in percent apoptotic cells. In contrast, the viability of BCL-2-expressing IM-9 cells cultured with 25 or 50 M Zoledronate was maintained above 90% and the development of apoptotic cells in culture was prevented. The different sensitivities to cytotoxicity between the two cell lines correlated with different sensitivities to DNA cleavage ( Figure 6 ). As shown, neo-control IM-9 cells show endonucleosomal DNA degradation when exposed to Zoledronate (lane 10) but the BCL-2-transfected cells are resistant (lane 13). Thus, enforced BCL-2 expression curtails apoptotic death of plasma cells induced by bisphosphonates. However, although cell death was prevented, enforced BCL-2 expression was incapable of protecting against the cytostasis induced by bisphosphonates. In these same cultures where BCL-2-transfected IM-9 cell viability was maintained Ͼ90%, the cell recovery (compared to non-treated BCL-2-transfected cells), which is a measure of cytostasis as well as cytolysis, was 32 and 68% of control after 48 h exposure to 50 and 25 M Zoledronate, respectively. In addition, MTT assays also demonstrated a similar cytostasis in BCL-2-expressing IM-9 cells which was seen as 48 and 25% cytotoxicity following 48 h exposure to 50 and 25 M Zoledronate.
Discussion
The stimulus for these studies was the finding that myeloma patients on salvage chemotherapy, who were randomized to also receive Pamidronate (Aredia) instead of placebo, enjoyed a significant survival advantage. This raises the question of whether bisphosphonate infusions can induce anti-tumor effects in addition to their ameliorating effects on myelomaassociated osteolytic bone complications. The results of our study indicate that these agents can adversely affect myeloma cell growth and viability in vitro via a direct interaction between drug and MM target cell. Dose-and time-dependent cytotoxic effects were demonstrated on MM cell lines as well as three freshly obtained MM specimens from patients. Cytoreductive effects were demonstrated by dye exclusion and MTT assays. At least part of these effects could be attributed to the induction of apoptotic death. Apoptosis was confirmed by morphologic analysis, DNA electrophoresis and flow cytometry. Apoptosis of patient MM specimens was also confirmed.
It should be mentioned that two of the MM cell lines we used (ARH-77 and IM-9) are, in fact, EBV-positive lymphoblastoid cell lines with a phenotype that differs from other EBVnegative MM cell lines. 18 It is possible that their distinct phenotype might be related to their relative resistance to bisphosphonates as ARH-77 cells were completely unaffected and IM-9 cells were significantly less affected compared to the EBV-negative classical MM cell lines.
Since bisphosphonates chelate calcium, 13 and extracellular calcium tends to be a viability-promoting factor, it was possible that cytotoxicity was simply an artifact with cell death due to a deficiency in the viability-maintaining property of extracellular calcium. However, concurrent experiments with the more efficient calcium chelator EGTA (Figure 3) confirm that Pamidronate's cytotoxic effect is not due to chelation of extracellular calcium. Furthermore, simultaneous exposure to Pamidronate plus EGTA resulted in decreased rather than increased cytotoxicity, further ruling out the notion that Pami- dronate acts via chelation of calcium and suggesting that a decrease in extracellular calcium concentrations can actually protect targets. Interestingly, the bisphosphonate alendronate induces leakiness for calcium in osteoclasts which results in a rise in free intracellular cytosolic calcium (Ca I ). 19 Such a rise in Ca I has been previously suggested as an inhibitory signal for osteoclasts. 20, 21 Furthermore, induced increases in Ca I have also been indicted as second messengers during induction of apoptosis. 22, 23 These studies are consistent with the hypothesis that bisphosphonate-induced increases in Ca I in MM cells play a role in the detected cytotoxicity in our studies.
Since bisphosphonates can down-regulate production of IL-6 from other types of cells 14 and IL-6 is a known potent growth factor of MM cells, 24 we also considered the possibility that decreased MM cell growth and survival was an indirect effect, secondary to a decreased production of IL-6 from bisphosphonate-treated plasma cells. This was ruled out since exogenous IL-6 was incapable of reversing cytotoxicity in our cell lines, especially in the IL-6-autocrine U266 MM cell line. The IL-6 experiments also suggest that bisphosphonateinduced MM cell death is mediated by pathways that differ from dexamethasone-or anti-fas-induced death since, in the latter, IL-6 is protective.
In addition to the detection of apoptotic sub-G1 cells on cell cycle analysis, a dose-dependent increase in the proportion of cells in the S-phase was also seen in bisphosphonate-treated cultures. This consistent alteration, possibly due to slowing of progression through S phase or a block between S and G2M, suggests that, in addition to inducing apoptotic cell death, the bisphosphonates inhibit proliferation. Prior reports have shown that these drugs can inhibit proliferation of other cell types. 25, 26 This notion was further confirmed in assays that tested the effects of enforced BCL-2 expression. BCL-2-transfected cells were completely protected against bisphosphonate-induced apoptotic death and demonstrated normal viabilities and intact DNA. However, they were still significantly inhibited in their proliferation as shown by a marked bisphosphonate-induced decrease in recovery and cytotoxicity in MTT assays (which measures both survival vs death as well as effects on proliferation). The ability of BCL-2 to protect against death but not against inhibited proliferation is also seen in cultures challenged with chemotherapeutic agents. 27 Thus, bisphosphonates inhibit MM cell proliferation and induce MM cell death and these two events can be separated. It is possible, however, that the two events are associated as there are other examples of apoptosis being linked to cell cycle alterations. For example, it may be that the cells induced to undergo apoptosis are specifically those that are abnormally blocked or slowed in their S phase transit. We are in the process of studying whether bisphosphonates selectively kill cells in S phase.
Whether or not MM targets are uniquely sensitive to the apoptotic, cytotoxic and/or cytostatic effects of bisphosphonates is unclear. In a limited survey, we could not detect any adverse effect of these drugs (used between 1 and 100 M) on several other human and murine tumor cell lines. In similar fashion, there was no inhibitory effect of risedronate on in vitro growth of breast cancer cells when used up to 10 M. 28 However, we detected sensitivity in several osteoblast and osteogenic sarcoma lines (data not shown). In addition, previous studies detected apoptotic effects of bisphosphonates on isolated osteoclasts 6 and cells of the monocyte-macrophage lineage. 7 Of these targets, osteoclasts appear the most sensitive even in the absence of the concentrating effect of bone material 6 with significant cytotoxic effects seen at concentrations as low as 1 M Pamidronate. The reasons for these relative differences in sensitivity are unknown. They may be due to differential internalization rates, or downstream differences in proteins that generally regulate apoptosis such as the BCL family or ICE family of proteases. The relative sensitivities among our different plasma cell populations were specific for bisphosphonate-injury and not seen when plasma cells were challenged with other apoptosis-inducing agents.
A more relevant question is whether these cytotoxic concentrations of Pamidronate or Zoledronate can be reached in treated patients. Certainly, peak serum concentrations are far below the required threshold but, owing to the singular skeletal distribution of administered bisphosphonates, marrow concentrations may be sufficient to inhibit growth of myeloma cells. Not only are injected bisphosphonates concentrated in the bony skeleton, they become preferentially bound to skeletal sites of bone resorption. 19 These sites of active bone resorption are most likely adjacent to areas of myeloma growth in patients. 29 Furthermore, during bone resorption, an osteoclast-induced acidification in the immediate milieu would greatly release bound bisphosphonates, 19 resulting in a marked increase in local bisphosphonate concentration, which, for Alendronate, 19 has been estimated to reach as high as 800 M directly at the osteoclast-bone interface. This would certainly be a toxic concentration for malignant plasma cells but the bisphosphonate concentration away from the immediate vicinity of the resorbing osteoclast is unknown and, furthermore, it is unclear how long high concentrations in the vicinity are maintained. Theoretically, soon after acidification, release of bone-containing bisphosphonate and resulting high concentrations are reached, osteoclastmediated resorption would cease (owing to inhibition or death of osteoclasts), acidification would be terminated and free bisphosphonate concentrations would rapidly fall.
In addition to our observed adverse effects of bisphosphonates on MM cells, it is also possible that these drugs exert anti-tumor effects in patients by indirect mechanisms. Thus, bisphosphonates may inhibit the adhesiveness of circulating myeloma cells to bony matrix, preventing further myeloma tumor deposits within the skeleton. A similar inhibitory effect on breast cancer cell adhesion to bone was detected when bone slices were pre-incubated with several different bisphosphonates, including Pamidronate. 30 An additional anti-tumor effect might occur secondary to effects on MM cell growth factors. The bone marrow is an environment rich in potential tumor cell growth factors and bisphosphonates can potentially inhibit the production/release of these factors. For example, bisphosphonates can inhibit IL-6 release from osteoblast type cells 31 as well as from myeloma marrow stromal cell monolayers.
14 A subsequent decreased concentration of this myeloma growth factor could result in an anti-tumor effect. In addition, tumor cell growth factors may be released into the marrow environment as a result of bone resorption 32, 33 and inhibition of such resorption by bisphosphonates would, thus, also decrease this stimulus for tumor cell growth. A similar inhibition of bone resorption-associated tumor growth factors may account for an anti-tumor effect seen in bones of nude mice challenged with human breast cancer cells. 28 In summary, the two bisphosphonates Pamidronate and Zoledronate were found to be cytotoxic to MM plasma cells at concentrations between 10 and 100 M. These results, coupled with our earlier study demonstrating a survival advantage in Pamidronate-treated patients, suggest these agents may induce an anti-tumor effect in addition to their supportive effects on skeletal function. The ability of bisphosphonates to induce anti-tumor effects in animals 28, 30, 34 further supports this possibility. This hypothesis should be further tested in appropriate studies that are relevant to myeloma.
